XML 90 R74.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue - Additional Information (Detail) - Licensing Agreement [Member] - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Mar. 31, 2021
Jun. 30, 2023
Jun. 30, 2021
Oasmia [Member]      
Statement [line items]      
Upfront payment received     $ 4,000
Simcere Pharmaceutical Group Limited [Member]      
Statement [line items]      
Upfront payment received $ 11,000    
Upfront payment received in cash 7,000    
Upfront payment received in shares $ 4,000    
Premium on investment percentage 20.00%    
Oasmia And Simcere Pharmaceutical Group [Member]      
Statement [line items]      
Revenue recognized out of consideration received from customers during the period   $ 0  
Oasmia Pharmceutical AB And Sincere Pharmaceuticals Group Limited [Member]      
Statement [line items]      
Revenue from performance obligations satisfied or partially satisfied in previous periods     11,000
Commercial Milestone [Member] | Oasmia [Member]      
Statement [line items]      
Contingent milestone payment receivable     42,000
Commercial Milestone [Member] | Simcere Pharmaceutical Group Limited [Member]      
Statement [line items]      
Contingent milestone payment receivable     $ 281,000